Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma

International Journal of Clinical Pharmacology and Therapeutics

Volumn 38, Issue 1, 2000, Pages 41-44

  Martens Lobenhoffer, J ^a,c   Fuhlroth, J ^b   Ridwelski, K ^b  

^a Inst of Pharmacology and Toxicology   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

5 fluorouracil; Amifostine; Pharmacokinetics

Indexed keywords

AMIFOSTINE; FLUOROURACIL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; GAS CHROMATOGRAPHY; HUMAN; LIVER METASTASIS; MALE; MASS SPECTROMETRY;

EID: 0033978262     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP38041     Document Type: Article

References (10)

1. Anderson D, Kerr DJ, Blesing C, Seymour LW 1997 Simultaneous gas chromatographic-mass spectrophotometric determination of alpha-fluoro-beta-alanine and 5-FU in plasma. J Chromatogr B Biomed Sci Appl 688: 87-93
2. Diasio RB, Harris BE 1989 Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215-237
3. Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, Maillet ML, Goudier MJ, Sire M, Person-Joly MC, Maigre M, Maillart P, Fety R, Burtin P, Lortholary A, Dumesnil Y, Picon L, Geslin J, Gesta P, Danquechin-Dorval E, Larra F, Robert J 1998 Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 16: 1470-1478
4. Fahlke J, Ridwelski K, Lippert H 1999 High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal, carcinoma. Int J Colorectal Dis 14: 128-130
5. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J 1996 Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14: 2101-2112
6. Korst AE, van der Sterre ML, Gall HE, Fichtinger-Schepman AM, Vermorken JB, van der Vijgh WJ 1998 Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. Clin Cancer Res 4: 331-336
7. Nowakowska-Dulawa E 1990 Circadian rhythm of 5-fluoroluracil (FU) pharmacokinetics and tolerance. Chronobiologia 17: 27-35
8. Schaaf LJ, Dobbs BR, Edwards IR, Perrier DG 1987 Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in clorectal cancer patients. Eur J Clin Pharmacol 32: 411-418
9. Van der Vijgh WJF, Peters GJ 1994 Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects. Semin Oncol 21: 2-7
10. Weh HJ, Wilke HJ, Dierlamm J, Klaassen U, Siegmund R, Illiger HJ, Schalhorn A, Kreuser ED, Hilgenfeld U, Steinke B, Weber W, Burkhard O, Zoller A, Pfitzner J, Subert R, Kriebel R, Hossfeld DK 1994 Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 5: 233-237